Proteome Sciences plc (AIM:PRM)

Market Cap	7.38M
Revenue (ttm)	4.53M
Net Income (ttm)	-3.33M
Shares Out	295.18M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	748,966
Average Volume	219,239
Open	2.800
Previous Close	2.255
Day's Range	2.100 - 3.000
52-Week Range	1.300 - 5.400
Beta	0.30
RSI	60.85
Earnings Date	Apr 2, 2026

About Proteome Sciences

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling p...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1993
• Employees: 36
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: PRM

Financial Performance

In 2024, Proteome Sciences's revenue was 4.89 million, a decrease of -2.80% compared to the previous year's 5.03 million. Losses were -3.41 million, 39.4% more than in 2023.